Drug intelligence / Profile preview

LY231514 tetra glu

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules

Overview

LY231514 tetra glu is an experimental small molecule drug belonging to the class of pentacarboxylic acids and derivatives. It has been studied as a potential anticancer agent. Its primary mechanism of action is inhibition of thymidylate synthase (in yeast), an enzyme critical for DNA synthesis and repair, making it a candidate for antineoplastic therapy. The compound has not received regulatory approval in the US or elsewhere and does not have any approved indications. There are no reported clinical trials beyond preclinical or discovery phases[1][4].

Targets

TS (Thymidylate synthase)

Beyond the preview

Go deeper on LY231514 tetra glu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY231514 tetra glu.

Explore the full profile